Skip to main content

Table 1 Characteristics of appendiceal cancer patients treated with or without chemotherapy in 1998–2016

From: Chemotherapy in the treatment of different histological types of appendiceal cancers: a SEER based study

Variable

All ptients

Chemotherapy status

P value

(n = 8733)

No (n = 5957)

Yes (n = 2776)

 

Age

 Mean ± SD

56.3 ± 16.4

56.2 ± 18

56.6 ± 12.3

< 0.0001

 Median (range)

57 (18–99)

57 (18–99)

57 (19–89)

 

  ≤ 56

5075 (58.1)

2885 (48.4)

1351 (48.7)

0.4273

  > 56

3658 (41.9)

3072 (51.6)

1425 (51.3)

 

Gender

 Male

3947 (45.2)

3276 (68.5)

1510 (31.6)

0.0603

 Female

4786 (54.8)

2681 (67.9)

1266 (32.1)

 

Marital status

 Marrieda

5067 (58)

3215 (63.5)

1852 (36.6)

< 0.0001

 Unmarried

3262 (37.4)

2423 (74.3)

839 (25.7)

 

 Unknown

404 (4.6)

319 (79)

85 (21)

 

Race

 African American

854 (9.8)

576 (67.5)

278 (32.6)

0.0001

 White

7299 (83.6)

4994 (68.4)

2305 (31.6)

 

 Other

515 (5.9)

328 (63.7)

187 (36.3)

 

 Unknown

65 (0.7)

59 (90.8)

6 (9.2)

 

Region

 West

4185 (47.9)

2899 (69.3)

1286 (30.7)

0.0803

 South

2078 (23.8)

1410 (67.9)

668 (32.2)

 

 Midwest

824 (9.4)

535 (64.9)

289 (35.1)

 

 Northwest

1646 (18.9)

1113 (67.6)

533 (32.4)

 

CEA

 Negative

1126 (12.9)

513 (45.6)

613 (54.4)

< 0.0001

 Positive

1097 (12.6)

430 (39.2)

667 (60.8)

 

 Unknown

6510 (74.5)

5014 (77)

1496 (23)

 

Tumor deposit

 Negative

2222 (25.4)

1391 (62.6)

831 (37.4)

< 0.0001

 Positive

438 (5)

128 (29.2)

310 (70.8)

 

 Unknown

6073 (69.5)

4438 (73.1)

1635 (26.9)

 

Tumor size

  < 2 cm

2742 (31.4)

2467 (90)

275 (10)

< 0.0001

  ≥ 2 cm

3668 (42)

2086 (56.9)

1582 (43.1)

 

 Unknown

2323 (26.6)

1404 (60.4)

919 (39.6)

 

Harvested lymph nodes

  ≤ 12

5098 (58.4)

3804 (74.6)

1294 (25.4)

< 0.0001

  > 12

3527 (40.4)

2093 (59.3)

1434 (40.7)

 

 Unknown

108 (1.2)

60 (55.6)

48 (44.4)

 

Histology

 GCC

1087 (12.5)

927 (85.3)

160 (14.7)

< 0.0001

 MAC

2831 (32.4)

1518 (53.6)

1313 (46.4)

 

 NMAC

1762 (20.2)

1046 (59.4)

716 (40.6)

 

 SRCC

575 (6.6)

207 (36)

368 (64)

 

 NECs

421 (4.8)

400 (95)

21 (5)

 

 NETs

1667 (19.1)

1640 (98.4)

27 (1.6)

 

 MiNENs

390 (4.5)

219 (56.2)

171 (43.9)

 

T stage

 T1

2224 (25.5)

2122 (35.6)

102 (3.7)

< 0.0001

 T2

748 (8.6)

682 (11.5)

66 (2.4)

 

 T3

2680 (30.7)

1904 (32)

776 (28)

 

 T4

3081 (35.3)

1249 (21)

1832 (66)

 

N stage

 N0

6984 (80)

5293 (88.9)

1691 (60.9)

< 0.0001

 N1

1096 (12.6)

454 (7.6)

642 (23.1)

 

 N2

653 (7.5)

210 (3.5)

443 (16)

 

M stage

 M0

6604 (75.6)

5267 (79.8)

1337 (20.3)

< 0.0001

 M1

2129 (24.4)

690 (32.4)

1439 (67.6)

 

Grade

 Well differentiated

3015 (34.5)

2475 (82.1)

540 (17.9)

< 0.0001

 Moderately differentiated

2320 (26.6)

1411 (60.8)

909 (39.2)

 

 Poorly or un-differentiated

1403 (16.1)

576 (41.1)

827 (59)

 

 Unknown

1995 (22.8)

1495 (74.9)

500 (25.1)

 

Surgery

 Less than hemicolectomy

3847 (44.1)

3075 (79.9)

772 (20.1)

< 0.0001

 Hemicolectomy or more

4406 (50.5)

2600 (59)

1806 (41)

 

 Other

480 (5.5)

282 (58.8)

198 (41.3)

 

Cancer specific death

 No

7024 (80.4)

5232 (74.5)

1792 (25.5)

< 0.0001

 Yes

1709 (19.6)

725 (42.4)

984 (57.6)

 

Overall death

 No

6000 (68.7)

4456 (74.3)

1544 (25.7)

< 0.0001

 Yes

2733 (31.3)

1501 (54.9)

1232 (45.1)

 
  1. aUnmarried status, including divorced, separated, widowed and unmarried. SRCC signet ring cell carcinoma; MAC, mucinous adenocarcinomas; NMAC, non-mucinous adenocarcinoma; MiNENs mixed neuroendocrine non-neuroendocrine neoplasms; GCC goblet cell carcinoma; NETs neuroendocrine tumors; NECs neuroendocrine carcinomas